The prevalence and impact of thrombocytopenia, anaemia and leucopenia on sustained virological response in patients receiving hepatitis C therapy: evidence from a large ‘real world’ cohort

Huan Wang, Hamish Innes, Sharon Hutchinson, David Goldberg, Samuel Allen, Stephen T. Barclay, Peter Bramley, Raymond Fox, Andrew Fraser, Peter Hayes, Nicholas Kennedy, Peter R. Mills, John F. Dillon

Research output: Contribution to journalArticle

52 Downloads (Pure)

Abstract

The aim of the study was to explore the extent of thrombocytopenia (TCP), anaemia and leucopenia in patients with hepatitis C and evaluate how they impact the management of antiviral therapy, the attainment of sustained virological response (SVR), and some therapy-related adverse events. The Scottish Hepatitis C Clinical Database was used in this retrospective study. The prevalence of TCP, anaemia and leucopenia was evaluated. The impact of the three deficiencies on antiviral therapy management, serious adverse events and SVR attainment was assessed in patients who received therapy.
Original languageEnglish
Pages (from-to)398-404
Number of pages7
JournalEuropean Journal of Gastroenterology and Hepatology
Volume28
Issue number4
Early online date21 Dec 2015
DOIs
Publication statusPublished - Apr 2016

Keywords

  • thrombocytopenia
  • Hepatitis C
  • antiviral therapy

Fingerprint Dive into the research topics of 'The prevalence and impact of thrombocytopenia, anaemia and leucopenia on sustained virological response in patients receiving hepatitis C therapy: evidence from a large ‘real world’ cohort'. Together they form a unique fingerprint.

  • Cite this